Skip to main content
. 2016 Feb 1;7(11):12344–12358. doi: 10.18632/oncotarget.7111

Figure 4. Therapeutic assessment of CXCR4-mAb in H1155 and A549 NSCLC tumor xenograft models.

Figure 4

Therapeutic studies (n=7 per cohort) with CXCR4-mAb, control-mAb or vehicle administered at a dose of 10 mg/kg every third day illustrate a significant reduction in tumor growth in high-CXCR4 H1155 tumors treated with CXCR4-mAb A. further confirmed by tumor weights post-therapy C, E. studies in low-CXCR4 A549 xenografts do not show clear therapeutic response B. also reflected in the final tumor weights D, F. BrdU staining (scale 50μm) of excised tumor tissues G. and quantification of the BrdU staining signal intensity H. showed a significant decrease in proliferation in high-CXCR4 H1155 tumors and no significant changes in proliferation for low-CXCR4 A549 tumors, further confirming that treatment response correlates with levels of CXCR4 expression; p<0.05 *, <0.01 **, <0.001***, <0.0001****; n.s. denotes not statistically significant.